Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis

Panizzutti, Bruna; Skvarc, David; Lin, Sylvia; Croce, Sarah; Meehan, Alcy; Bortolasci, Chiara C.; Marx, Wolfgang; Walker, Adam J.; Hasebe, Kyoko; Kavanagh, Bianca E; Morris, Margaret J.; Mohebbi, Mohammadreza; Turner, Alyna; Gray, Laura J.; Berk, Lesley; Walder, Ken; Berk, Michael; Dean, Olivia

doi:10.3390/ijms24065250

Cited by 17 publications

(7 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there are contradictory results regarding the direction of cytokine level changes that could result from different disease stages and patient conditions, disturbances in cytokine levels and interactions may be significant contributors to schizophrenia pathophysiology [55]. Agents affecting inflammation such as minocycline and celecoxib have been explored in schizophrenia with variable results [56][57][58].…”

Section: Discussionmentioning

confidence: 99%

Network-based drug repurposing for schizophrenia

Truong,

Liu,

Panizzutti

et al. 2024

Neuropsychopharmacol.

Self Cite

View full text Add to dashboard Cite

Despite recent progress, the challenges in drug discovery for schizophrenia persist. However, computational drug repurposing has gained popularity as it leverages the wealth of expanding biomedical databases. Network analyses provide a comprehensive understanding of transcription factor (TF) regulatory effects through gene regulatory networks, which capture the interactions between TFs and target genes by integrating various lines of evidence. Using the PANDA algorithm, we examined the topological variances in TF-gene regulatory networks between individuals with schizophrenia and healthy controls. This algorithm incorporates binding motifs, protein interactions, and gene co-expression data. To identify these differences, we subtracted the edge weights of the healthy control network from those of the schizophrenia network. The resulting differential network was then analysed using the CLUEreg tool in the GRAND database. This tool employs differential network signatures to identify drugs that potentially target the gene signature associated with the disease. Our analysis utilised a large RNA-seq dataset comprising 532 post-mortem brain samples from the CommonMind project. We constructed co-expression gene regulatory networks for both schizophrenia cases and healthy control subjects, incorporating 15,831 genes and 413 overlapping TFs. Through drug repurposing, we identified 18 promising candidates for repurposing as potential treatments for schizophrenia. The analysis of TF-gene regulatory networks revealed that the TFs in schizophrenia predominantly regulate pathways associated with energy metabolism, immune response, cell adhesion, and thyroid hormone signalling. These pathways represent significant targets for therapeutic intervention. The identified drug repurposing candidates likely act through TF-targeted pathways. These promising candidates, particularly those with preclinical evidence such as rimonabant and kaempferol, warrant further investigation into their potential mechanisms of action and efficacy in alleviating the symptoms of schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Network-based drug repurposing for schizophrenia

Truong,

Liu,

Panizzutti

et al. 2024

Neuropsychopharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Minocycline is a broad-spectrum tetracycline antibiotic, which, primarily, is used to treat bacterial infections but also has a neuroprotective, anti-inflammatory, and antioxidant effect [ 290 , 291 ]. Hence, it became an object of interest as an adjunctive treatment for psychiatric and neurobiological conditions [ 292 ].…”

Section: Therapeutic Targetsmentioning

confidence: 99%

Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?

Suprunowicz,

Tomaszek,

Urbaniak

et al. 2024

Nutrients

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) is a neuropsychiatric condition characterized by impaired social interactions and repetitive stereotyped behaviors. Growing evidence highlights an important role of the gut–brain–microbiome axis in the pathogenesis of ASD. Research indicates an abnormal composition of the gut microbiome and the potential involvement of bacterial molecules in neuroinflammation and brain development disruptions. Concurrently, attention is directed towards the role of short-chain fatty acids (SCFAs) and impaired intestinal tightness. This comprehensive review emphasizes the potential impact of maternal gut microbiota changes on the development of autism in children, especially considering maternal immune activation (MIA). The following paper evaluates the impact of the birth route on the colonization of the child with bacteria in the first weeks of life. Furthermore, it explores the role of pro-inflammatory cytokines, such as IL-6 and IL-17a and mother’s obesity as potentially environmental factors of ASD. The purpose of this review is to advance our understanding of ASD pathogenesis, while also searching for the positive implications of the latest therapies, such as probiotics, prebiotics or fecal microbiota transplantation, targeting the gut microbiota and reducing inflammation. This review aims to provide valuable insights that could instruct future studies and treatments for individuals affected by ASD.

show abstract

“…Systematic reviews and meta-analyses suggest that minocycline may have potential benefits in treating PSD, especially when combined with psychiatric interventions and antiinflammatory strategies. These studies emphasize the role of minocycline in regulating neuroinflammation, oxidative stress and neuroprotection, offering new pharmacological options for PSD treatment [209].…”

Section: Psychiatric Interventions Combined With Antiinflammatory Str...mentioning

confidence: 99%

Inflammatory Pathogenesis of Post-stroke Depression

2024

Aging dis

View full text Add to dashboard Cite

Post-stroke depression (PSD) is a complex mood disorder that emerges in individuals following a stroke, characterized by the development of depressive symptoms. The pathogensis of PSD is diverse, with inflammation playing a vital role in its onset and progression. Emerging evidence suggests that microglial activation, astrocyte responses, nuclear factor κB(NF-κB) signaling, dysregulation of the hypothalamic pituitary adrenal (HPA) axis, alterations in brain-derived neurotrophic factor (BDNF) expression, neurotransmitter imbalances, adenosine triphosphate (ATP) and its receptors and oxidative stress are intricately linked to the pathogenesis of PSD. The involvement of inflammatory cytokines in these processes highlights the significance of the inflammatory pathway. Integrating these hypotheses, the inflammatory mechanism offers a novel perspective to expand therapeutic strategies for PSD.

show abstract

Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis

Cited by 17 publications

References 72 publications

Network-based drug repurposing for schizophrenia

Network-based drug repurposing for schizophrenia

Between Dysbiosis, Maternal Immune Activation and Autism: Is There a Common Pathway?

Inflammatory Pathogenesis of Post-stroke Depression

Contact Info

Product

Resources

About